|
1
|
Kim HR, Oh IJ, Shin MG, et al: Plasma
proGRP concentration is sensitive and specific for discriminating
small cell lung cancer from nonmalignant conditions or non-small
cell lung cancer. J Korean Med Sci. 26:625–630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jung KW, Won YJ, Kong HJ, et al: Cancer
statistics in Korea: incidence, mortality, survival and prevalence
in 2010. Cancer Res Treat. 45:1–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
4
|
van Zandwijk N: New methods for early
diagnosis of lung cancer. Lung Cancer. 38:S9–S11. 2002.PubMed/NCBI
|
|
5
|
Altiay G, Ciftci A, Demir M, et al: High
plasma D-dimer level is associated with decreased survival in
patients with lung cancer. Clin Oncol (R Coll Radiol). 19:494–498.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Falanga A and Rickles FR: Pathophysiology
of the thrombophilic state in the cancer patient. Semin Thromb
Hemost. 25:173–182. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kwaan HC and Keer HN: Fibrinolysis and
cancer. Semin Thromb Hemost. 16:230–235. 1990. View Article : Google Scholar
|
|
8
|
Unsal E, Atalay F, Atikcan S and Yilmaz A:
Prognostic significance of hemostatic parameters in patients with
lung cancer. Respir Med. 98:93–98. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu D, Zhou X, Yang G, et al: Clinical
performance of the AMDL DR-70 immunoassay kit for cancer detection.
J Immunoassay. 19:63–72. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oya M, Akiyama Y, Yanagida T, Akao S and
Ishikawa H: Plasma D-dimer level in patients with colorectal
cancer: its role as a tumor marker. Surg Today. 28:373–378. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gerner C, Steinkellner W, Holzmann K, et
al: Elevated plasma levels of crosslinked fibrinogen gamma-chain
dimer indicate cancer-related fibrin deposition and fibrinolysis.
Thromb Haemost. 85:494–501. 2001.
|
|
12
|
Lin SZ, Chen CC, Lee KC, et al: DR-70
immunoassay for the surveillance of hepatocellular carcinoma. J
Gastroenterol Hepatol. 27:547–552. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stieber P, Dienemann H, Hasholzner U, et
al: Comparison of cytokeratin fragment 19 (CYFRA 21–1), tissue
polypeptide antigen (TPA) and tissue polypeptide specific antigen
(TPS) as tumour markers in lung cancer. Eur J Clin Chem Clin
Biochem. 31:689–694. 1993.
|
|
14
|
Pujol JL, Grenier J, Daurès JP, Daver A,
Pujol H and Michel FB: Serum fragment of cytokeratin subunit 19
measured by CYFRA 21–1 immunoradiometric assay as a marker of lung
cancer. Cancer Res. 53:61–66. 1993.PubMed/NCBI
|
|
15
|
Takada M, Masuda N, Matsuura E, et al:
Measurement of cytokeratin 19 fragments as a marker of lung cancer
by CYFRA 21-1 enzyme immunoassay. Br J Cancer. 71:160–165. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stieber P, Hasholzner U, Bodenmuller H, et
al: CYFRA 21-1. A new marker in lung cancer. Cancer. 72:707–713.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma J, Gong Q, Lin M, et al: Combined five
tumor markers in detecting primary hepatic carcinoma. Zhonghua Wai
Ke Za Zhi. 38:14–16. 2000.(In Chinese).
|
|
18
|
Kerber A, Trojan J, Herrlinger K, Zgouras
D, Caspary WF and Braden B: The new DR-70 immunoassay detects
cancer of the gastrointestinal tract: a validation study. Aliment
Pharmacol Ther. 20:983–987. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Qiao Z, Long X, Wei J and Cheng Y:
Serum concentration of AMDL DR-70 for the diagnosis and prognosis
of carcinoma of the tongue. Br J Oral Maxillofac Surg. 43:513–515.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee KH, Cho DH, Kim KM, Kim SM and Lee DJ:
Meaning of the DR-70(TM) immunoassay for patients with the
malignant tumor. Immune Netw. 6:43–51. 2006. View Article : Google Scholar
|
|
21
|
Shimwell NJ, Wei W, Wilson S, et al:
Assessment of novel combinations of biomarkers for the detection of
colorectal cancer. Cancer Biomark. 7:123–132. 2010.PubMed/NCBI
|
|
22
|
Ward DG, Wei W, Buckels J, et al:
Detection of pancreatic adenocarcinoma using circulating fragments
of fibrinogen. Eur J Gastroenterol Hepatol. 22:1358–1363. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Small-Howard AL and Harris H: Advantages
of the AMDL-ELISA DR-70 (FDP) assay over carcinoembryonic antigen
(CEA) for monitoring colorectal cancer patients. J Immunoassay
Immunochem. 31:131–147. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Buccheri G, Torchio P and Ferrigno D:
Plasma levels of D-dimer in lung carcinoma: clinical and prognostic
significance. Cancer. 97:3044–3052. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pavey SJ, Hawson GA and Marsh NA: Impact
of the fibrinolytic enzyme system on prognosis and survival
associated with non-small cell lung carcinoma. Blood Coagul
Fibrinolysis. 12:51–58. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brambilla E, Travis WD, Colby TV, et al:
The new World Health Organization classification of lung tumours.
Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fields A, Poppema S and Jha Nl: Serum
levels of circulating extracellular matrix complex (CEMC) in lung
cancer patients: potential use as a tumor marker. In: 12th
International Conference on Human Tumor Markers; New York, USA.
June 11–14, 1995;
|
|
28
|
Wu D, Zhou X, Anderson G, et al:
Sensitivity and specificity of DR-70 lung cancer immunology. Anal
Lett. 32:1351–1362. 1999. View Article : Google Scholar
|
|
29
|
Ding L, Ping S and Jingmei Y: Application
of tumor marker of DR-70 in the diagnosis of malignant tumors.
Chongqing Med J. 28:1–3. 1999.
|
|
30
|
Kao CH, Hsieh JF, Ho YJ, Tsai SC and Lee
JK: Cytokeratin fragment 19 (CYFRA 21-1) in healthy smokers.
Anticancer Res. 19:4545–4546. 1999.PubMed/NCBI
|
